Barratt, Jonathan http://orcid.org/0000-0002-9063-7229
Dellanna, Frank
Portoles, Jose
Choukroun, Gabriel
De Nicola, Luca
Young, James
Dimković, Nada
Reusch, Michael
Clinical trials referenced in this document:
Documents that mention this clinical trial
Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study
https://doi.org/10.1681/asn.2020081150
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
https://doi.org/10.1007/s12325-023-02433-0
Documents that mention this clinical trial
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD
https://doi.org/10.34067/kid.0001442022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
https://doi.org/10.1681/asn.2020111638
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
https://doi.org/10.1007/s12325-023-02728-2
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
https://doi.org/10.1007/s12325-023-02433-0
Documents that mention this clinical trial
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD
https://doi.org/10.34067/kid.0001442022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
https://doi.org/10.1681/asn.2020111638
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
https://doi.org/10.1053/j.ajkd.2015.12.020
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
https://doi.org/10.1007/s12325-023-02728-2
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
https://doi.org/10.1007/s12325-023-02433-0
Documents that mention this clinical trial
Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD
https://doi.org/10.34067/kid.0001442022
Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
https://doi.org/10.1681/asn.2020111638
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
https://doi.org/10.1007/s12325-023-02728-2
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
https://doi.org/10.1007/s12325-023-02433-0
Funding for this research was provided by:
Astellas Pharma, Inc.
Article History
Received: 21 December 2022
Accepted: 13 January 2023
First Online: 7 February 2023